The Alzheimer’s Disease Atlas (“the Atlas”) is an interactive digital platform designed to address the significant variation in how Alzheimer’s disease (AD) is managed across the globe. Launching in April 2026, with an initial focus on 80 countries, it provides a standardized way to view dementia care. The Atlas goes beyond simple statistics and focusing instead on the actual journey of care patients and their families take, while coping with AD, the most prevalent form of dementia.
To create a clear and helpful picture of the global landscape, we have gathered information from a wide variety of trusted sources, including peer-reviewed journals, official government records, and scientific literature. We then streamlined these findings to ensure they are accessible to everyone, not just specialists. Our goal is to turn complex data into a practical, easy-to-navigate resource that provides meaningful insights for families, healthcare professionals, and anyone navigating the road ahead.
Through its interactive map, comparison tool, and individual country profiles, users can see exactly how different nations are tackling the challenges that come with a dementia diagnosis and learn more about available treatment and care. The Atlas serves as a hub for information on innovative diagnostic tools that are being developed, as well as services aimed at patients and their caregivers.
Rather than looking at the disease through a narrow clinical lens, the Atlas breaks the landscape down into five essential categories that matter to the community:
1. Diagnosis
This category maps the diagnostic pathway patients encounter in each country profiled territory. It outlines the tools currently in use – such as cognitive and imaging tests, along with biomarker analysis and genetic profiling), it lists the estimated wait times and diagnosis costs. The goal is to present a realistic scenario of what an individual may encounter on their way towards a diagnosis.
2. Treatment and Care
The reality of living with AD and dementia is presented by examining both medical options and physical care infrastructure. This category catalogues the regulatory status of medications, distinguishing between long standing symptomatic treatments and the new wave of innovative disease-modifying therapies. However, caring for dementia extends beyond medications – theAtlas also maps the physical network of specialized facilities and services, including but not limited to memory clinics and day care centres, while describing support options for caregivers. Treatment costs and availability of financial assistance are covered in this section.
3. Policy
The legislative and strategic frameworks often determine how a country prioritizes dementia; by mapping the existence of national dementia plans, and by listing the upcoming strategies, the Atlas aims to simplify and explain the policy that stands behind the government’s plans for tackling the growing number of persons whose lives are affected by AD and dementia. Often, persons deal with not only the disease itself, but also with cultural and legal barriers – issues the Atlas covers in the Policy gaps subsection.
4. Research
This category identifies the centres of excellence and academic hubs that are pushing the boundaries of what we know about AD. It provides a window into the future by tracking clinical trial registries and the development of innovative methods, such as AI-driven diagnostics, non-invasive retinal scans, and revolutionary blood tests. By mapping the network of specialized research hubs and the specific methodologies they employ, the Atlas illustrates the level of global commitment dedicated to refining early detection and improving our biological understanding of the disease.
5. Support
In most countries, long-term assistance is often provided by family members; this section of the Atlas maps the non-governmental landscape – often the most vital support systems for persons living with dementia and their families, highlighting the NGOs, patient associations, and community-led initiatives – like “dementia villages” or “carer cafés” – that step in to provide the training, psychological counselling, and social connection that the state often cannot.
The Atlas is a shared journey between Alzheimer’s Disease International (ADI) and Eli Lilly and Company (Lilly). As the global federation for Alzheimer and dementia associations, ADI represents the voices and needs of member association from more than 100 countries. This project was made possible through Lilly’s financial support and collaboration, with ADI ensuring the platform serves as a trusted, community-focused resource for everyone.
We’ve designed this platform to be an informational guide. While we hope the data here provides valuable clarity, it’s important to remember that it is not intended to replace professional medical or legal advice. The inclusion of any specific organization, product, or service is simply to provide a complete picture of the landscape and does not imply a formal endorsement.